Tempest Therapeutics (TPST) Expected to Announce Quarterly Earnings on Tuesday

Tempest Therapeutics (NASDAQ:TPST) is expected to be releasing its earnings data before the market opens on Tuesday, March 18th. Analysts expect Tempest Therapeutics to post earnings of ($0.24) per share for the quarter.

Tempest Therapeutics Price Performance

NASDAQ:TPST opened at $0.84 on Monday. Tempest Therapeutics has a 1-year low of $0.70 and a 1-year high of $6.00. The business has a 50 day moving average of $0.89 and a 200 day moving average of $1.01. The company has a market capitalization of $36.64 million, a price-to-earnings ratio of -0.55 and a beta of -1.83.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.